Published in Maturitas on September 24, 2004
Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci (2013) 1.06
High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam Cancer (2012) 1.02
Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors. Oncotarget (2012) 0.89
EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics (2011) 0.89
A review of the molecular mechanisms of chemically induced neoplasia in rat and mouse models in National Toxicology Program bioassays and their relevance to human cancer. Toxicol Pathol (2009) 0.81
The molecular genetics of breast cancer and targeted therapy. Biologics (2007) 0.81
Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer. BMC Res Notes (2012) 0.81
Identification of rare germline copy number variations over-represented in five human cancer types. Mol Cancer (2015) 0.78
Genetic polymorphisms associated with breast cancer in malaysian cohort. Indian J Clin Biochem (2014) 0.77
BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle (2016) 0.75
Secretion of N- and O-linked Glycoproteins from 4T1 Murine Mammary Carcinoma Cells. Int J Med Sci (2016) 0.75
Estimating genomic instability mediated by Alu retroelements in breast cancer. Genet Mol Biol (2009) 0.75
Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem (1998) 1.90
Laparoscopic skills training using inexpensive box trainers: which exercises to choose when constructing a validated training course. BJOG (2011) 1.67
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology (2003) 1.59
HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer (2012) 1.53
Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol (1998) 1.40
DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol (2007) 1.40
Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol (2002) 1.36
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer (2007) 1.30
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol (2006) 1.24
Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol (2002) 1.21
Training and learning robotic surgery, time for a more structured approach: a systematic review. BJOG (2011) 1.14
HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv (2004) 1.10
Robotic surgery. BJOG (2009) 1.08
Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem (1993) 1.01
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer (2006) 0.98
Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett (1997) 0.94
Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: a retrospective cohort study. BJOG (2012) 0.92
Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis. Ultrasound Obstet Gynecol (2012) 0.90
Clinical trials in ovarian carcinoma: study methodology. Ann Oncol (2005) 0.90
Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin Chem (1997) 0.88
Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer (2003) 0.87
Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG (2007) 0.86
Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer (2007) 0.85
Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value. Clin Chem (1997) 0.83
From open radical hysterectomy to robot-assisted laparoscopic radical hysterectomy for early stage cervical cancer: aspects of a single institution learning curve. Gynecol Surg (2010) 0.83
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer (1996) 0.83
'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumour Biol (1998) 0.82
Comparison of bleomycin and radiation in the G2 assay of chromatid breaks. Int J Radiat Biol (2003) 0.81
T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2001) 0.81
HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. Histopathology (2007) 0.80
Thalidomide in refractory haemorrhagic radiation induced proctitis. Gut (2006) 0.80
Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod (1999) 0.80
High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol (2012) 0.80
The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis. BJOG (2014) 0.79
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol (2002) 0.79
In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosus is mainly of undifferentiated type: new insights in histology and aetiology. J Clin Pathol (2006) 0.79
[Trophoblastic diseases]. Ned Tijdschr Geneeskd (2008) 0.78
Vaccination against HPV: indications for women and the impact on the cervical screening programme. BJOG (2008) 0.78
Digital colposcopy: ready for use? An overview of literature. BJOG (2009) 0.78
Oncological outcome and long-term complications in robot-assisted radical surgery for early stage cervical cancer: an observational cohort study. BJOG (2014) 0.77
Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumour Biol (2000) 0.77
Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas (2009) 0.76
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.76
A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature. Int J Gynecol Cancer (2007) 0.76
HrHPV-testing in a university hospital gynecology outpatient clinic: recommendations for clinical practice. Gynecol Oncol (2011) 0.75
Quantification of MUC1 in breast cancer patients. A method comparison study. Eur J Obstet Gynecol Reprod Biol (1999) 0.75
Multicenter evaluation of the Abbott IMx CA 15-3 assay. Clin Chem (1996) 0.75
Women's Preferences of Dynamic Spectral Imaging Colposcopy. Gynecol Obstet Invest (2014) 0.75
Systematic lymphadenectomy in patients with clinical stage II endometrial carcinoma: a case report and review of the literature. Eur J Gynaecol Oncol (2012) 0.75
Serum CA-125 concentrations during midfollicular phase, a clinically useful and reproducible marker in diagnosis of advanced endometriosis. Clin Chem (1996) 0.75
Effect of hormones on the expression of proviral genes Mtv-2 and Mtv-3 in mouse mammary gland. Int J Cancer (1983) 0.75